Donald Chase Buys 12,500 Shares of Bluejay Diagnostics (NASDAQ:BJDX) Stock

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Director Donald Chase acquired 12,500 shares of the company’s stock in a transaction dated Saturday, March 14th. The stock was purchased at an average cost of $2.00 per share, for a total transaction of $25,000.00. Following the purchase, the director directly owned 12,525 shares in the company, valued at approximately $25,050. This represents a 50,000.00% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through this link.

Bluejay Diagnostics Stock Performance

BJDX opened at $1.71 on Wednesday. Bluejay Diagnostics, Inc. has a one year low of $1.62 and a one year high of $16.68. The stock’s fifty day moving average is $1.89 and its 200-day moving average is $3.14. The company has a market capitalization of $1.76 million, a PE ratio of -0.15 and a beta of 0.72.

Bluejay Diagnostics (NASDAQ:BJDX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.95) EPS for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

Hedge Funds Weigh In On Bluejay Diagnostics

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC bought a new position in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned about 9.15% of Bluejay Diagnostics as of its most recent SEC filing. 18.47% of the stock is currently owned by institutional investors and hedge funds.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.